A practical reference on REV-ERB: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
=== Pediatric drug testing === Prior to the 1990s, only 20% of all drugs prescribed for children in the United States were tested for safety or efficacy in a pediatric population. This became a major concern of pediatricians as evidence accumulated that the physiological response of children to many drugs differed significantly from those drugs' effects on adults. Children react differently to the drugs because of many reasons, including size, weight, etc. There were several reasons that few medical trials were done with children. For many drugs, children represented such a small proportion of the potential market, that drug manufacturers did not see such testing as cost-effective. Also, the belief that children are ethically restricted in their ability to give informed consent brought increased governmental and institutional hurdles to approval of these clinical trials, and greater concerns about legal liability. Thus, for decades, most medicines prescribed to children in the U.S. were done so in a non-FDA-approved, "off-label" manner, with dosages "extrapolated" from adult data through body weight and body-surface-area calculations. In an initial FDA attempt to address this issue they produced the 1994 FDA Final Rule on Pediatric Labeling and Extrapolation, which allowed manufacturers to add pediatric labeling information, but required drugs that had not been tested for pediatric safety and efficacy to bear a disclaimer to that effect. However, this rule failed to motivate many drug companies to conduct additional pediatric drug trials.
Site-specific recombination makes use of phage integrases instead of restriction enzymes, eliminating the need for having restriction sites in the DNA fragments. Instead, integrases make use of unique attachment (att) sites, and catalyse DNA rearrangement between the target fragment and the destination vector. The Invitrogen Gateway cloning system was invented in the late 1990s and uses two proprietary enzyme mixtures, BP clonase and LR clonase. The BP clonase mix catalyses the recombination between attB and attP sites, generating hybrid attL and attR sites, while the LR clonase mix catalyse the recombination of attL and attR sites to give attB and attP sites. As each enzyme mix recognises only specific att sites, recombination is highly specific and the fragments can be assembled in the desired sequence. Vector design and assembly Because Gateway cloning is a proprietary technology, all Gateway reactions must be carried out with the Gateway kit that is provided by the manufacturer. The reaction can be summarised into two steps. The first step involves assembling the entry clones containing the DNA fragment of interest, while the second step involves inserting this fragment of interest into the destination clone.
Some bats prey on other vertebrates, such as fish, frogs, lizards, birds and mammals. The fringe-lipped bat (Trachops cirrhosus), for example, is skilled at catching frogs, locating them by tracking their mating calls. The greater noctule bat (Nyctalus lasiopterus) hunts and catches birds in flight. Some species, like the greater bulldog bat (Noctilio leporinus), hunt fish, flying over the water and grabbing them with their clawed feet. They use echolocation and may be alerted by ripples on the surface or a jumping fish. Some species feed on other bats, including the spectral bat (Vampyrum spectrum) and the ghost bat (Macroderma gigas).
Sources: en.wikipedia.org
A potentially controversial method of producing biopharmaceuticals involves transgenic organisms, particularly plants and animals that have been genetically modified to produce drugs. This production is a significant risk for its investor due to production failure or scrutiny from regulatory bodies based on perceived risks and ethical issues. Biopharmaceutical crops also represent a risk of cross-contamination with non-engineered crops, or crops engineered for non-medical purposes. One potential approach to this technology is the creation of a transgenic mammal that can produce the biopharmaceutical in its milk, blood, or urine. Once an animal is produced, typically using the pronuclear microinjection method, it becomes efficacious to use cloning technology to create additional offspring that carry the favorable modified genome. The first such drug manufactured from the milk of a genetically modified goat was ATryn, but marketing permission was blocked by the European Medicines Agency in February 2006. This decision was reversed in June 2006 and approval was given August 2006.
Several aircraft and helicopters were damaged in a storm on 1 July 2017 that struck the air force's main base at N'Djamena International Airport. The severity of the storm was amplified by the use of fabric hangar coverings. Losses or damaged equipment included three helicopters, a PC-12, a MiG-29 fighter, and two Su-25 attack planes. The force shared a base with French forces at N'Djamena International Airport until January 2025 when the French withdrew.
BALB/c is an albino laboratory-bred strain from which a number of common substrains are derived. With over 200 generations bred since 1920, BALB/c mice are distributed globally and are among the most widely used inbred strains used in animal experimentation. BALB/c are noted for displaying high levels of anxiety and for being relatively resistant to diet-induced atherosclerosis, making them a useful model for cardiovascular research. Male BALB/c mice are aggressive and will fight other males if housed together. However, the BALB/Lac substrain is much more docile. Most BALB/c mice substrains have a long reproductive life-span. There are noted differences between different BALB/c substrains, though these are thought to be due to mutation rather than genetic contamination. The BALB/cWt is unusual in that 3% of progeny display true hermaphroditism.
More than 500 Olympic champions lived in Moscow as of 2005. The city contains 63 stadiums—in addition to 8 football and 11 light athletics maneges (indoor sports halls); of these, Luzhniki Stadium is the largest in Moscow and the fourth largest in Europe. This stadium hosted the 1998–99 UEFA Cup, the 2007–08 UEFA Champions League finals, the 1980 Summer Olympics, and the 2018 FIFA World Cup (with 7 games in total, including the final). Forty other sports complexes are located in the city, including 24 complexes featuring artificial ice. The Olympic Stadium in Moscow was the world's first indoor arena for bandy, and it hosted the Bandy World Championship twice. Moscow hosted this competition again in 2010, at the Krylatskoye rink. This rink has also hosted the World Speed Skating Championships. In addition, Moscow contains seven horse racing tracks, of which the Central Moscow Hippodrome (founded in 1834) is the largest.
Sources: en.wikipedia.org
==== MeSH E05.318.760 – epidemiologic study characteristics ==== MeSH E05.318.760.500 – epidemiologic studies MeSH E05.318.760.500.500 – case-control studies MeSH E05.318.760.500.500.500 – retrospective studies MeSH E05.318.760.500.750 – cohort studies MeSH E05.318.760.500.750.500 – longitudinal studies MeSH E05.318.760.500.750.500.350 – follow-up studies MeSH E05.318.760.500.750.500.650 – prospective studies MeSH E05.318.760.500.875 – cross-sectional studies MeSH E05.318.760.500.950 – seroepidemiologic studies MeSH E05.318.760.500.950.375 – hiv seroprevalence MeSH E05.318.760.535 – clinical trials MeSH E05.318.760.535.200 – clinical trials, phase i MeSH E05.318.760.535.210 – clinical trials, phase ii MeSH E05.318.760.535.220 – clinical trials, phase iii MeSH E05.318.760.535.230 – clinical trials, phase iv MeSH E05.318.760.535.365 – controlled clinical trials MeSH E05.318.760.535.365.500 – randomized controlled trials MeSH E05.318.760.535.500 – multicenter studies MeSH E05.318.760.550 – feasibility studies MeSH E05.318.760.565 – intervention studies MeSH E05.318.760.750 – pilot projects MeSH E05.318.760.875 – sampling studies MeSH E05.318.760.900 – twin studies
== Biosynthesis == 2,5-DKPs are synthesized by a variety of organisms including humans. In general, they arise by the action of a tRNA-dependent cyclodipeptide synthases, a type of enzyme responsible for creating a cyclic amide linkage between two peptides. The enzymes cyclodipeptide oxidase and S-adenosyl-methionine-dependent O/N methyltransferases act in tandem to chemically modify cyclic dipeptides.
== Chemistry == The chemical structure of suvomipic was originally undisclosed for a time. The drug has been patented and its structure was initially said to be known only to Pelage Pharmaceuticals. The company has also patented and published on other MPC inhibitors such as JXL069 and JXL082. They are (E)-2-cyano-3-(1H-indol-3-yl)acrylic acids and related analogues. Suvomipic was said to be neither JXL069 nor JXL082. The drug-related properties of certain related MPC inhibitors like UK-5099 (JXL001) are said to be incompatible with therapeutic use. In July 2026, the INNTooltip International Nonproprietary Name of suvomipic was published and revealed it to in fact be JXL069.
The specimen NIGP 127587 was preserved with the remains of a lizard in its gut region, indicating that small, fast-moving animals made up part of the diet of Sinosauropteryx prima. Numerous lizards of this type have been found in the same rocks as Sinosauropteryx. These lizards have been interpreted as most likely belonging to the genus Dalinghosaurus. Dalinghosaurus was probably a fast-running lizard adapted to living in open habitats, much like Sinosauropteryx itself. The previously attributed Sinosauropteryx specimen GMV 2124 (Sinosauropteryx? sp.) was found with three mammal jaws in its gut region. Hurum, Luo, and Kielan-Jaworowska (2006) identified two of these jaws as belonging to Zhangheotherium and the third to Sinobaatar, showing that these two mammals were part of the animal's diet. Zhangheotherium is known to have had a spur on the ankle, like the modern platypus, which would indicate that Sinosauropteryx fed on possibly venomous mammals. However, this specimen was later reclassified as a tyrannosauroid.
=== Support groups === The Juvenile Scleroderma Network is an organization dedicated to providing emotional support and educational information to parents and their children living with juvenile scleroderma, supporting pediatric research to identify the cause of and the cure for juvenile scleroderma, and enhancing public awareness. In the US, the Scleroderma Foundation is dedicated to raise awareness of the disease and assist those who are affected. The Scleroderma Research Foundation sponsors research into the condition. Comedian and television presenter Bob Saget, a board member of the SRF, directed the 1996 ABC TV movie For Hope, starring Dana Delany, which depicts a young woman fatally affected by scleroderma; the film was based on the experiences of Saget's sister Gay. Scleroderma and Raynaud's UK is a British charity formed by the merger of two smaller organisations in 2016 to provide support for people with scleroderma and fund research into the condition.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.